Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter
FLORHAM PARK, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity"), a regenerative and cellular medicine company, today announced that the Nasdaq Listing Qualifications Hearings Panel (the "Hearings Panel") has cancelled the previously scheduled hearing regarding Celularity's non-compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), as the Company has cured its filing delinquency. The matter is now closed, and Nasdaq has confirmed that Celularity's stock will continue to be listed and traded on The Nasdaq Stock Market.
新澤西州佛羅哈姆公園,2024年11月18日(全球新聞網)-- Celularity Inc.(納斯達克:CELU)("Celularity"),一家再生和細胞醫學公司,今天宣佈納斯達克上市資格聽證委員會("聽證委員會")已取消之前安排的關於Celularity未遵守納斯達克上市規則5250(c)(1)("規則")的聽證會,因爲公司已糾正其提交逾期問題。此事現已結束,納斯達克確認Celularity的股票將繼續在納斯達克證券市場上市和交易。
This resolution follows Nasdaq's prior notification on October 16, 2024, indicating that Celularity was not in compliance with the Rule due to the delayed filing of its quarterly reports on Forms 10-Q for the periods ended March 31, 2024, and June 30, 2024. As disclosed, Celularity filed an appeal and amended compliance plan with the Hearings Panel, seeking an extension to regain compliance. Subsequently, Celularity filed its Form 10-Q for the period ended March 31, 2024, on October 16, 2024, and its Form 10-Q for the period ended June 30, 2024, on November 7, 2024, achieving compliance with Nasdaq requirements.
此解決方案是基於納斯達克於2024年10月16日發出的先前通知,指出Celularity因未能按時提交截至2024年3月31日和6月30日的四分之一報告表格10-Q而未遵守該規則。如披露,Celularity向聽證會議小組提出上訴並修訂了符合計劃,尋求延期以恢復合規性。隨後,Celularity於2024年10月16日提交了截至2024年3月31日的10-Q表格,並於2024年11月7日提交了截至2024年6月30日的10-Q表格,符合納斯達克的要求。
"We are pleased to have met Nasdaq's requirements and to resolve this matter, allowing us to continue trading on The Nasdaq Stock Market," said Robert J. Hariri, M.D., Ph.D., Founder, Chairman, and CEO of Celularity. "This milestone reflects our dedication to transparency and regulatory compliance. We remain committed to building a robust foundation to support timely financial reporting and our mission to harness the potential of the placenta to develop transformative therapies."
"我們很高興滿足了納斯達克的要求並解決了這一問題,使我們能夠繼續在納斯達克股票市場上交易," Celularity的創始人、主席兼首席執行官Robert J. Hariri博士表示。"這一里程碑反映了我們對透明度和監管合規性的承諾。我們致力於建立強大的基礎,以支撐及時的財務報告和利用胎盤潛力開發變革性療法的使命。"
The delays in filing were primarily due to significant financial challenges impacting the biotechnology sector, which restricted access to capital and affected Celularity's ability to secure essential audit and financial advisory services. Despite these challenges, Celularity implemented meaningful process improvements, including engaging EisnerAmper LLP as its independent audit firm and enhancing internal controls.
提交延誤主要是由影響生物技術行業的重大財務挑戰造成的,這些挑戰限制了對資本的獲取,並影響了Celularity獲得必要審計和財務諮詢服務的能力。儘管面臨這些挑戰,Celularity實施了有意義的流程改進,包括聘請EisnerAmper LLP作爲其獨立審計公司,並加強內部控制。
About Celularity
Celularity Inc. (Nasdaq: CELU) is a regenerative medicine company developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. Celularity believes that by harnessing the placenta's unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies. For more information, visit .
關於Celularity
Celularity公司(NASDAQ:CELU)是一家創新的再生和細胞醫學公司。它正在開發和商業化先進的生物材料產品和由胎盤衍生的異基因、冷凍保存的細胞治療,所有這些產品都來自於派產後胎盤。Celularity的治療計劃,以用mesenchymal-like黏附性基質細胞(MLASCs)和加有CAR的T細胞、經過基因修飾或未經修飾的天然殺傷細胞(NK細胞)治療老齡相關疾病爲目標,包括退行性疾病、癌症和免疫功能紊亂。Celularity獨特的方法利用胎盤的生物學和提供的便利性,正在爲治療解決在全球範圍內的重大未滿足需求提供開創性的解決方案。
Celularity Inc.(納斯達克:CELU)是一家再生醫學公司,專注於開發和商業化先進的生物材料產品以及來自產後胎盤的異體、冷凍保存、胎盤衍生電芯療法。其治療方案旨在針對與衰老相關的疾病,包括退行性疾病、癌症和免疫紊亂,使用基質樣黏附性間充質細胞(MLASCs)萬億電芯,經過CAR修飾的(CAR t細胞)以及基因改造和未改造的自然殺傷(NK)細胞。Celularity相信,通過利用胎盤獨特的生物學特性和現成的可獲取性,可以開發出滿足全球有效、可及且負擔得起的治療方案的重要未滿足需求的治療解決方案。有關更多信息,請訪問。
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as well as within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are "forward-looking statements," including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "believe," "can," "contemplate," "continue," "could," "estimate," "expect," "forecast," "intends," "may," "might," "outlook," "plan," "possible," "potential," "predict," "project," "seek," "should," "strive," "target," "will," "would" and the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. The forward-looking statements in this press release include express or implied statements regarding Celularity's ability to strengthen its financial and operational processes, its ability to timely addressing any financial reporting backlog, and the impact of any improvements on long term growth or success. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including but not limited to: Celularity's liquidity situation; the volatility in Celularity's stock price; inherent risks in biotechnological development, including with respect to the development of novel advanced biomaterials; and the regulatory approval process; along with those risk factors set forth under the caption "Risk Factors" in Celularity's annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on July 30, 2024, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity's current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity's views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date hereof, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
前瞻性聲明
本新聞稿包含根據1995年美國《證券訴訟改革法》(U.S. Private Securities Litigation Reform Act)以及修改後的1933年《美國證券法》第27A條和1934年《美國證券交易法》第21E條的定義屬於"前瞻性聲明"。除歷史事實陳述之外的所有陳述均屬於"前瞻性聲明",包括涉及未來事件的陳述。在某些情況下,您可以根據"預期"、"相信"、"可以"、"考慮"、"繼續"、"可能"、"預計"、"估計"、"預測"、"打算"、"可以"、"可能"、"計劃"、"可能"、"潛在"、"預測"、"項目"、"尋找"、"應該"、"努力"、"目標"、"將"、"將會"等術語識別出前瞻性聲明,或者通過其否定形式或其他類似術語的詞語或類似含義的詞語。本新聞稿中的前瞻性聲明包括對Celularity增強其財務和運營流程能力的明示或暗示聲明,對其及時解決任何財務報告積壓的能力以及任何改進對長期增長或成功的影響。許多因素可能導致實際結果與這些前瞻性聲明中描述的結果有實質性差異,包括但不限於:Celularity的流動性狀況;Celularity股價的波動性;生物技術發展中的固有風險,包括與先進生物材料開發相關的風險和監管審批過程;以及在Celularity於2024年7月30日向證券交易委員會(SEC)提交的10-K表格年度報告中所列風險因素下所列風險因素。如果這些風險中的任何一個出現或基礎假設證明不正確,實際結果可能會與這些前瞻性聲明所隱含的結果有實質性差異。Celularity目前不知道的可能存在其他風險或Celularity目前認爲不重要的風險可能也會導致實際結果不同於前瞻性聲明中包含的結果。此外,這些前瞻性聲明反映了Celularity對未來事件的當前期望、計劃或預測,並截至本通信日期。隨後事件和發展可能導致評估發生變化。因此,不應僅憑前瞻性聲明作爲Celularity在任何隨後日期意見的依據,並且Celularity不承諾更新前瞻性聲明以反映此後事件或情況,無論是基於新信息、未來事件或其他原因,除非根據適用證券法可能要求。
Investor Contact:
Carlos Ramirez
Senior Vice President, Celularity Inc.
Carlos.ramirez@celularity.com
投資者聯繫人:
卡洛斯·拉米雷斯
Celularity公司高級副總裁
Carlos.ramirez@celularity.com
Media Contacts:
Raquel Cona / Michaela Fawcett
KCSA Strategic Communications
rcona@kcsa.com / mfawcett@kcsa.com
媒體聯繫方式:
Raquel Cona / Michaela Fawcett
KCSA戰略傳播
rcona@kcsa.com / mfawcett@kcsa.com